A registrational trial of narazaciclib for the treatment of low grade endometrioid endometrial cancer (LGEEC)
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Narazaciclib (Primary)
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
Most Recent Events
- 02 Apr 2024 According to a Onconova Therapeutics media release, Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 21 Nov 2023 New trial record
- 14 Nov 2023 According to an Onconova Therapeutics media release, the company provides an update on our registrational trial-readiness over the next few quarters, including the definition of our recommended Phase 2 dose, engagement with the FDA on the pivotal trial design, and continuing to work with external clinical experts including the Gynecologic Oncology Group (GOG), and the European Network for Gynecologic Oncology Trials (ENGOT).